Sarepta Therapeutics (SRPT +12.9%) continues to be on a tear following a 14.3% gain yesterday. Talk has been swirling around the company's Eteplirsen treatment for Duchenne muscular dystrophy, including a report by a Missouri news station that a boy showed marked improvement using the drug in clinical trials. Options activity in the name has been active, with call volume leaping 700% over its daily average.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs